Skip to main content
Download PDF
- Main
MEK Inhibitor-Based Combination Strategies in Selected Molecular Subsets of Non-Small Cell Lung Cancer (NSCLC): rationale for the Design of Phase I Clinical Trials
The data associated with this publication are not available for this reason: NA
Abstract
Lung cancer is the leading cause of both cancer and cancer-related mortality in the United States. Targeting different receptor tyrosine kinase pathways has proven to be a potent therapeutic strategy for such cancers.
Main Content
For improved accessibility of PDF content, download the file to your device.
Enter the password to open this PDF file:
File name:
-
File size:
-
Title:
-
Author:
-
Subject:
-
Keywords:
-
Creation Date:
-
Modification Date:
-
Creator:
-
PDF Producer:
-
PDF Version:
-
Page Count:
-
Page Size:
-
Fast Web View:
-
Preparing document for printing…
0%